This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Pulmonary Arterial Hypertension
and you are
over 18
years old
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

A multinational, multicenter, double blind, placebo-controlled study evaluating the efficacy and safety of imatinib as an add-on therapy in the treatment of patients with severe pulmonary arterial hypertension (PAH).

Provided treatments

  • Drug: imatinib mesylate
  • Drug: Placebo
Tris trial is registered with FDA with number: NCT00902174. The sponsor of the trial is Novartis Pharmaceuticals and it is looking for 202 volunteers for the current phase.
Official trial title:
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)